Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sintilimab With P-GemOx (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type (ENKTL): a Single Arm, Open, Multicenter, Phase II Study

NCT04127227 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT04127227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04127227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sintilimab With P-GemOx (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type (ENKTL): a Single Arm, Open, Multicenter, Phase II Study
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 9, 2019
Completion date
October 9, 2027
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nk/t cell lymphoma nos